Showing results (261-270 of 566) with videos related to

Sort By:
Pageof 57
Current Medical Research and Opinion|May 26, 2021
Immune-mediated diseases and thromboembolic events: a modified Delphi panelNassir Azimi, Freddy Caldera, Stan Cohen, et al.
The Journal of Rheumatology|January 14, 2004
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)Daniel E Furst, Michael H Schiff, Roy M Fleischmann, et al.
The Lancet. Rheumatology|May 5, 2025
Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trialVibeke Strand, Kenneth C Kalunian, Kai Wai Lee, et al.
Rheumatology and Therapy|November 10, 2023
Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment Selection in Rheumatoid ArthritisJeffrey R Curtis, Vibeke Strand, Steven J Golombek, et al.
The Journal of Rheumatology. Supplement|June 2, 2004
Leflunomide: a manageable safety profilePeit L C M van Riel, Josef S Smolen, Paul Emery, et al.
RMD Open|July 6, 2022
Is the Rheumatoid Arthritis Impact of Disease (RAID) score a meaningful instrument for other inflammatory rheumatic diseases? A cross-sectional analysis of data from the German National DatabaseKatja Thiele, Katinka Albrecht, Angela Zink, et al.
Lupus|January 6, 2021
Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohortAnna Kernder, Jutta G Richter, Rebecca Fischer-Betz, et al.
Arthritis Research & Therapy|October 31, 2019
The impact of sex and disease classification on patient-reported outcome measures in axial spondyloarthritis: a descriptive prospective cross-sectional studyRikke A Andreasen, Lars E Kristensen, Kenneth Egstrup, et al.
The Journal of Rheumatology|July 15, 2023
Report of the Skin Research Workgroups From the IDEOM Breakout at the GRAPPA 2022 Annual MeetingMelissa P Zundell, Michael J Woodbury, Kathryn Lee, et al.
RMD Open|November 2, 2019
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trialVibeke Strand, Eduardo Mysler, Robert J Moots, et al.
Pageof 57